Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency. It also develops Chronocort, which completed Phase II clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early-stage pipeline products comprise Ditest, a native oral testosterone product, which has completed phase I clinical trial for the treatment of classical hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (triiodothyronine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.
Research context
Diurnal Group plc appears in PyInvesting’s London Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Diurnal Group plc is currently in a long term uptrend where the price is trading 3.9% above its 200 day moving average.
From a valuation standpoint, the stock is 96.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.1.
Diurnal Group plc's total revenue sank by 0.0% to $574K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 14.3% to $-2M since the same quarter in the previous year.
Based on the above factors, Diurnal Group plc gets an overall score of 3/5.